Archives
-
Tumor-Targeted Genetic Engineering Reinvigorates T Cells
2026-08-25
He et al. report PαCD3&LIGHT, a tumor-targeted plasmid that uses the TERT promoter to coordinate LIGHT-mediated immune-cell recruitment with membrane-anchored αCD3-mediated T-cell redirection. The approach suppresses several immune-cold solid tumor models and potentiates checkpoint inhibition and CAR-T therapy, while highlighting important translational questions concerning delivery, specificity, and safety.
-
How Lipid Choice Shapes mRNA-LNP Potency
2026-08-25
A 2025 Journal of Controlled Release study shows that comparable particle size, polydispersity, surface charge, and encapsulation efficiency do not guarantee comparable mRNA-LNP potency. By testing ionizable and PEGylated lipids in matched formulations in HEK293 cells and mice, the authors demonstrate why lipid identity and biological context must be evaluated together.
-
LNP Bleb Structures Improve mRNA Transfection
2026-08-24
Cheng and colleagues showed that mRNA-rich bleb structures can be induced in lipid nanoparticles containing less active ionizable lipids by changing the acidic formulation buffer. The resulting improvement in transfection was observed in vitro and in vivo and was linked, at least partly, to better preservation of encapsulated mRNA rather than simply more efficient intracellular delivery.
-
Ciprofloxacin, Zinc and RSL3 Ferroptosis
2026-08-24
The reference study identifies a stimulus-dependent role for ciprofloxacin in ferroptosis: although it previously protected cells from erastin-triggered death, it enhanced RSL3-induced ferroptosis by driving mitochondrial Zn2+ accumulation. Its mechanistic model connects topoisomerase 2β inhibition, mitochondrial DNA stress, the STING1–CAV2 pathway, SLC25A25-dependent zinc transport, and mitochondrial reactive oxygen species.
-
Firefly Luciferase mRNA Delivery Guide
2026-08-23
Build sensitive reporter assays with a Cap1-capped, 5-moUTP modified mRNA engineered for durable firefly luciferase expression. This guide connects practical transfection workflows with lipoplex design, in vivo imaging considerations, and troubleshooting strategies for more reproducible signal.
-
Firefly Luciferase mRNA: Assay Design Guide
2026-08-22
Firefly Luciferase mRNA (ARCA, 5-moUTP) is more than a luminescent readout: it is a tool for separating delivery, translation, metabolism, and assay performance. This guide connects reporter biology with emerging mRNA formulation research to improve experimental interpretation.
-
Ziprasidone HCl: From Permeability to Mechanism
2026-08-22
Explore how Ziprasidone HCl connects receptor pharmacology, GOT1 inhibition, and formulation-dependent permeability. This evidence-led guide translates nanocrystal findings into better assay design and interpretation for oncology and neuroscience research.
-
Phosbind Biotin LC Western Blot Guide
2026-08-21
Phosbind Biotin LC is a phosphate-binding reagent for sequence-independent detection of phosphorylated proteins on PVDF membranes when phospho-specific antibodies are unavailable or too narrowly targeted. It is intended for fresh, solvent-compatible Western Blot workflows with streptavidin-HRP and chemiluminescence, not aqueous-only protocols or long-term storage of prepared solutions.
-
H-Aggregated IR-1061 for NIR-II Cancer Therapy
2026-08-20
Yu et al. developed an RR9-functionalized anionic liposome that co-delivers IR-1061 and carboplatin while transferring the dye’s H-aggregated state to tumor cell membranes. The resulting platform integrates NIR-II fluorescence imaging with NIR-I photothermal therapy and temperature-responsive chemotherapy, offering a mechanistic strategy for improving image-guided cancer treatment.
-
EVMPs for Extrahepatic mRNA Delivery
2026-08-20
The reference study introduces a bottom-up, self-assembling enveloped virus-mimicking particle (EVMP) designed to overcome the hepatic bias of many mRNA delivery systems. By combining an engineered virus-mimicking peptide with tunable phospholipid envelopes, the authors achieved substantial lung delivery, therapeutic activity with IL-12 mRNA, and evidence supporting repeat administration.
-
GluN2A/2B–Connexin Signaling in TMJ Pain
2026-08-19
The reference study identifies distinct roles for the NMDAR subunits GluN2A and GluN2B in trigeminal ganglion sensitization during temporomandibular joint inflammation. Using conditional genetics, behavioral testing, satellite glial cell models, and pathway analysis, it connects NMDAR activity with connexin- and pannexin-mediated intercellular communication, particularly through ERK1/2 and related signaling pathways.
-
PDGF-BB for Pulmonary Vascular Remodeling Research
2026-08-19
Use murine recombinant PDGF-BB as a defined mitogenic control for smooth muscle cell proliferation, receptor-response profiling, and pulmonary hypertension workflows. Its documented BALB/c 3T3 potency and low endotoxin specification make it useful for separating growth-factor effects from hypoxia- and metabolism-driven phenotypes.
-
RNA Pol II Loss Activates Apoptosis Beyond Transcription
2026-08-18
Harper et al. show that RNA polymerase II inhibition kills cells through an active apoptotic program triggered by loss of hypophosphorylated RNA Pol IIA, rather than through transcriptional failure alone. Their PDAR model clarifies how diverse anticancer compounds can converge on RNA Pol II degradation-dependent mitochondrial death signaling and provides a framework for interpreting mechanistic cell-death assays.
-
ECL Chemiluminescent Substrate Detection Kit Guide
2026-08-18
Build a more sensitive western blot workflow for scarce targets, from membrane selection and antibody dilution to exposure timing and signal preservation. This guide shows how the hypersensitive ECL Chemiluminescent Substrate Detection Kit can support pathway-level validation in metabolic research while reducing background and conserving antibodies.
-
Trelagliptin, RUNX2, and Osteoblast Differentiation
2026-08-17
The reference study identifies a previously underexplored skeletal action of the DPP-4 inhibitor trelagliptin: enhancement of osteoblastic differentiation and mineralization in MC3T3-E1 cells through an AMPK-associated increase in RUNX2. Its findings provide a mechanistic basis for further investigation of trelagliptin in osteoporosis, while remaining preclinical and dependent on validation in primary cells and in vivo models.